# Efficacy and Safety of Lorundrostat in Subjects With Uncontrolled and Resistant Hypertension

> **NCT06153693** · PHASE3 · COMPLETED · sponsor: **Mineralys Therapeutics Inc.** · enrollment: 1083 (actual)

## Conditions studied

- Hypertension

## Interventions

- **DRUG:** Placebo
- **DRUG:** lorundrostat Dose 1
- **DRUG:** lorundrostat Dose 2

## Key facts

- **NCT ID:** NCT06153693
- **Lead sponsor:** Mineralys Therapeutics Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-11-22
- **Primary completion:** 2024-12-10
- **Final completion:** 2025-01-24
- **Target enrollment:** 1083 (ACTUAL)
- **Last updated:** 2026-05-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06153693

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06153693, "Efficacy and Safety of Lorundrostat in Subjects With Uncontrolled and Resistant Hypertension". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT06153693. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*